日本《胃癌治疗指南》的变更与胃癌治疗新动向
|
摘要
日本《胃癌治疗指南》(以下简称指南)目前已成为胃癌临床治疗的重要指导性文件,其每次更新均成为全球胃癌领域的重大事件,备受瞩目。2018年第5版指南发行,2019年2月在日本静冈召开的"第91届日本胃癌学会年会"再度对相关内容进行了严谨而深刻的讨论,提出了新的修改意见。随着新的循证医学证据的出现,指南也在不断更新,胃癌的治疗方式也不断与时俱进。
The Japanese Gastric Cancer Treatment Guidelines(referred to as "Guidelines") have become an important guiding document of the clinical treatment for gastric cancer,and the real-time updating of the Guidelines has become a major event in the field of gastric cancer worldwide, which has attracted much attention.The Guidelines-the 5 thedition had been released in 2018.Relevant contents of guidelines had been discussed again rigorously and profoundly at The 91 st Annual Meeting of The Japanese Gastric Cancer Association this year(February 2019,Shizuoka),and many new amendments and suggestions for diagnosis and treatment had been put forward.With the emergence of new evidence-based medical researches,the guidelines are constantly updated,and the treatment of gastric cancer is also improving with the times.
The Japanese Gastric Cancer Treatment Guidelines(referred to as "Guidelines") have become an important guiding document of the clinical treatment for gastric cancer,and the real-time updating of the Guidelines has become a major event in the field of gastric cancer worldwide, which has attracted much attention.The Guidelines-the 5 thedition had been released in 2018.Relevant contents of guidelines had been discussed again rigorously and profoundly at The 91 st Annual Meeting of The Japanese Gastric Cancer Association this year(February 2019,Shizuoka),and many new amendments and suggestions for diagnosis and treatment had been put forward.With the emergence of new evidence-based medical researches,the guidelines are constantly updated,and the treatment of gastric cancer is also improving with the times.
引文
[1]日本胃癌学会.日本胃癌学会編:胃癌治療ガイドライン-医師用年月改訂版[M].5版.東京:金原出版,2018.
[2]胡祥.第5版日本《胃癌治疗指南》拔萃[J].中国实用外科杂志,2018,38(4):396-406.
[3]胡祥.日本第15版《胃癌处理规约》及第5版《胃癌治疗指南》更新内容解读[J].中国实用外科杂志,2017,37(4):394-398.
[4]Fujitani K,Yang HK,Mizusawa J,et al.Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor(REGATTA):a phase 3,randomised controlled trial[J].Lancet Oncol,2016,17(3):309-318.
[5]Sano T,Sasako M,Mizusawa J,et al.Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma[J].Ann Surg,2017,265(2):277-283.
[6]Terashima MN,Ooki YC,Kurokawa YN,et al.Primary results of a phase 3 trial to evaluate bursectomy for patients with subsersal/serosal gastric cancer(JCOG 1001)[J].J Clin Oncl,2017,35(suppl 4):5.
[7]Yamashita H,Seto Y,Sano T,et al.Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma[J].Gastric Cancer,2017,20(suppl 1):69-83.
[8]Katai H,Sasako M,Fukuda H,et al.Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for cilinical stage 1 gastric cancer:a multicar phase 2 trail(JCOG 0703)[J].Gastric Cancer,2010,13(4):238-244.
[9]Noh SH,Park SR,Yang HK,et al.Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):5-year follow-up of an open-label,randomised phase 3 trial[J].Lancet Oncol,2014,15(12):1389-1396.
[10]Bang YJ,Kim YW,Yang HK,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label,randomised controlled trial[J].Lancet,2012,379(9813):315-321.
[11]Sakuramoto S,Sasako M,Yamaguchi T,et al.Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine[J].N Engl J Med,2007,357(18):1810-1820.
[12]Katai H,Mizusawa z,Katayama H,et al.Short-term surgical outcome from a phase 3 study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for cilinical stage1A/1B gastric cancer:Japan Clinical Oncology Group Stuay JCOG0912[J].Gastric Cancer,20(4):699-708.
[13]片井均.臨床試験紹介臨床病期I期胃癌に対する腹腔下胃全摘および腹腔下噴門側胃切除術の安全性に関する非ランダム化検証(JCOG1401)[J].胃癌Perspective,2016,8.
[14]Inaki N,Etoh T,Ohyama T,et al.A multi-institutional,prospective,phase ii feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer(JLSSG0901)[J].World J Surg,2015,39(11):2734-2741.
[15]Uyama I,Nakauchi M,Suda K,et al.Current status and future perspective of robotic gastrectomy for gastric cancer in Japan[C]//90th Annual Meeting of the Japanese Gastric Cancer Association,Yokohama:2018.
[16]Wilke H,Clingan P,Ananda S,et al.Rainbow:A global,phase3,double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of gastric cancer following disease progression:western population subgroup[J].Ann Oncol,2014,32(suppl 3):ii106-ii107.
[17]Takazawa K,Takashima A,Kimura A,et al.A phase2 clinical trial of endoscopic submucosal dissection for early gastric cancer of undifferentiatrd type Japan Clinical Oncology Group Study JCOG 1009/1010.91[J].Jpn J Clin Oncol,2013,43(1):87-91.
[18]Tsuburaya A,Mizusawa J,Tanaka Y,et al.Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J].Br J Surg,2014,101(6):653-660.
[19]Iwasaki Y,Terashima M,Mizusawa J,et al.Randomized phase3 trial of gastrectomy with or without neoadjuvant S-1plus cisplatin for type 4 or large type 3 gastric cancer:Japan Clinical Oncology Group Study(JCOG 0501)[J].J Clin Oncol,2018,36(suppl 15):4046.
[2]胡祥.第5版日本《胃癌治疗指南》拔萃[J].中国实用外科杂志,2018,38(4):396-406.
[3]胡祥.日本第15版《胃癌处理规约》及第5版《胃癌治疗指南》更新内容解读[J].中国实用外科杂志,2017,37(4):394-398.
[4]Fujitani K,Yang HK,Mizusawa J,et al.Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor(REGATTA):a phase 3,randomised controlled trial[J].Lancet Oncol,2016,17(3):309-318.
[5]Sano T,Sasako M,Mizusawa J,et al.Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma[J].Ann Surg,2017,265(2):277-283.
[6]Terashima MN,Ooki YC,Kurokawa YN,et al.Primary results of a phase 3 trial to evaluate bursectomy for patients with subsersal/serosal gastric cancer(JCOG 1001)[J].J Clin Oncl,2017,35(suppl 4):5.
[7]Yamashita H,Seto Y,Sano T,et al.Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma[J].Gastric Cancer,2017,20(suppl 1):69-83.
[8]Katai H,Sasako M,Fukuda H,et al.Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for cilinical stage 1 gastric cancer:a multicar phase 2 trail(JCOG 0703)[J].Gastric Cancer,2010,13(4):238-244.
[9]Noh SH,Park SR,Yang HK,et al.Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):5-year follow-up of an open-label,randomised phase 3 trial[J].Lancet Oncol,2014,15(12):1389-1396.
[10]Bang YJ,Kim YW,Yang HK,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label,randomised controlled trial[J].Lancet,2012,379(9813):315-321.
[11]Sakuramoto S,Sasako M,Yamaguchi T,et al.Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine[J].N Engl J Med,2007,357(18):1810-1820.
[12]Katai H,Mizusawa z,Katayama H,et al.Short-term surgical outcome from a phase 3 study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for cilinical stage1A/1B gastric cancer:Japan Clinical Oncology Group Stuay JCOG0912[J].Gastric Cancer,20(4):699-708.
[13]片井均.臨床試験紹介臨床病期I期胃癌に対する腹腔下胃全摘および腹腔下噴門側胃切除術の安全性に関する非ランダム化検証(JCOG1401)[J].胃癌Perspective,2016,8.
[14]Inaki N,Etoh T,Ohyama T,et al.A multi-institutional,prospective,phase ii feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer(JLSSG0901)[J].World J Surg,2015,39(11):2734-2741.
[15]Uyama I,Nakauchi M,Suda K,et al.Current status and future perspective of robotic gastrectomy for gastric cancer in Japan[C]//90th Annual Meeting of the Japanese Gastric Cancer Association,Yokohama:2018.
[16]Wilke H,Clingan P,Ananda S,et al.Rainbow:A global,phase3,double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of gastric cancer following disease progression:western population subgroup[J].Ann Oncol,2014,32(suppl 3):ii106-ii107.
[17]Takazawa K,Takashima A,Kimura A,et al.A phase2 clinical trial of endoscopic submucosal dissection for early gastric cancer of undifferentiatrd type Japan Clinical Oncology Group Study JCOG 1009/1010.91[J].Jpn J Clin Oncol,2013,43(1):87-91.
[18]Tsuburaya A,Mizusawa J,Tanaka Y,et al.Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J].Br J Surg,2014,101(6):653-660.
[19]Iwasaki Y,Terashima M,Mizusawa J,et al.Randomized phase3 trial of gastrectomy with or without neoadjuvant S-1plus cisplatin for type 4 or large type 3 gastric cancer:Japan Clinical Oncology Group Study(JCOG 0501)[J].J Clin Oncol,2018,36(suppl 15):4046.